In secondary analyses stratifying by event subtype, buprenorphine was associated with decreased opioid-specific poisonings across individuals with cooccurring SUD (OR, 0.51 [95% CI, 0.43-0.61]) and without cooccurring SUD (OR, 0.49 [95% CI, 0.44-0.55]), with similar associations observed for ER naltrexone (eFigure in the Supplement). While oral naltrexone was associated with decreased opioid-specific admissions for individuals with cooccurring SUD (OR, 0.53 [95% CI, 0.36-0.77]), no association was observed among individuals without cooccurring SUD. Notably, while buprenorphine exhibited protective associations with decreased nonopioid poisonings among individuals with cooccurring SUD (OR, 0.64 [95% CI, 0.49-0.85]) and those without cooccurring SUD (OR, 0.79 [95% CI, 0.67-0.94]), no protective associations were observed for ER or oral naltrexone with nonopioid poisonings (eFigure in the Supplement).
